Edgewise Therapeutics, Inc.
A clinical-stage biopharmaceutical company in Boulder, Colorado that makes swallowed pills designed to treat serious muscle diseases. Its drugs tune myosin, the protein that drives muscle contraction, to protect fragile fibers in muscular dystrophies and to ease the stiff, thickened heart muscle of hypertrophic cardiomyopathy. Founded in 2017 by four scientists and drug developers, the company went public on Nasdaq in 2021.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Paradigm BioCapital Advisors LP | 13G/APassive | 9.5% | 10.22M | Aug 14, 2026 |
| Paradigm BioCapital Advisors GP LLC | 13G/APassive | 9.5% | 10.22M | Aug 14, 2026 |
| Senai Asefaw, M.D. | 13G/APassive | 9.5% | 10.22M | Aug 14, 2026 |
| Paradigm BioCapital International Fund Ltd. | 13G/APassive | 8.3% | 8.96M | Aug 14, 2026 |
| RA Capital Management, L.P. | 13G/APassive | 7.8% | 8.39M | Aug 14, 2026 |
| Peter Kolchinsky | 13G/APassive | 7.8% | 8.39M | Aug 14, 2026 |
| Rajeev Shah | 13G/APassive | 7.8% | 8.39M | Aug 14, 2026 |
| RA Capital Healthcare Fund, L.P. | 13G/APassive | 7.8% | 8.39M | Aug 14, 2026 |
| Baker Bros. Advisors LP | 13G/APassive | 3.4% | 3.70M | Aug 14, 2026 |
| Baker Bros. Advisors (GP) LLC | 13G/APassive | 3.4% | 3.70M | Aug 14, 2026 |